
|Videos|May 2, 2022
Unpacking the need to accelerate clinical studies in retina
Author(s)David Hutton, Emily Kaiser Maharjan
Dr David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.
Advertisement
David Hutton, executive editor of Ophthalmology Times®, sits down with David Bingaman, DVM, PhD, Chief Development Officer of Ora Clinical to discuss the need to accelerate clinical trials and increase investments in retina research. Dr. Bingaman also discusses Ora Clinical’s presence at ARVO 2022.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
AAO 2026: Optogenetic gene therapy heads to phase 2 trial in geographic atrophy
2
AAO 2026: BRUNELLO 1-year results for remigromig in DME
3
AAO 2026: MCO-010 sustains vision gains in RP through 4 years
4
AAO 2026: DAYBREAK shows tarcocimab and tabirafusp-ted noninferior to aflibercept in wet AMD
5


















